Two-year Double-masked Comparison of Bimatoprost with Timolol in Patients with Glaucoma or Ocular Hypertension

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 1, 2004, Pages

  Cohen, John S ^a,d   Gross, Ronald L ^b   Cheetham, Janet K ^c   Vandenburgh, Amanda M ^c   Bernstein, Paula ^c   Whitcup, Scott M ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ALLERGAN INC   (United States)

^d CINCINNATI EYE INSTITUTE   (United States)

Author keywords

Antihypertensive agents; Bimatoprost; Hypotensive lipids therapeutic use; Intraocular pressure; Ocular hypertension; Open angle glaucoma; Timolol

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; METOPROLOL; TIMOLOL;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PIGMENTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UVEITIS;

AMIDES; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SAFETY; TIMOLOL;

EID: 1542328115     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.019     Document Type: Article

References (15)

1. The advanced glaucoma intervention study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 130:2000;429-440.
2. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 102:1995;1743-1752.
3. Boger W.P. 3rd. Short-term "escape" and long-term "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 28:(Suppl):1983;235-242.
4. Brandt J.D., VanDenburgh A.M., Chen K., Whitcup S.M. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology. 108:2001;1023-1031. discussion 1032.
5. Camras C.B., Alm A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 103:1996;1916-1924.
6. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 126:1998;487-497.
7. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 120:2002;1268-1279.
8. Higginbotham E.J., Schuman J.S., Goldberg I., et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
9. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;701-713. discussion 829-30.
10. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 121:2003;48-56.
11. Schuman J.S. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 107:2000;1171-1177.
12. Sherwood M., Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 45:(Suppl 4):2001;S361-S368.
13. Steinert R.F., Thomas J.V., Boger W.P. 3rd. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 99:1981;100-103.
14. Stjernschantz J.W., Albert D.M., Hu D.N., et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 47:(Suppl 1):2002;S162-S175.
15. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41:(Suppl 2):1997;S129-S138.